The FDA has postponed its advisory meeting to debate whether HRA Pharma’s birth control drug Opill should be authorized for over-the-counter use.
Read the full post on Becker's Hospital Review - Healthcare News
FDA delays meeting to discuss 1st OTC birth control pill
